De Novo Pharmaceuticals announces a Drug Discovery Partnership agreement with Achaogen
"We are very pleased to be working with Achaogen- a leader in the fight against drug-resistant bacteria," said Philip Dean, Ph.D., CSO at De Novo. "Using SkelGen, we will be designing for Achaogen new chemical classes of inhibitors focused on an important drug-resistant bacterial target", he added.
"We are pleased to be working with De Novo to expand our lead optimization program, and to help us develop cutting-edge therapeutics that will speed us towards our goal of providing therapies to treat unmet clinical needs caused by multi-drug resistant bacterial infections," said Phillip Patten, Ph.D., Senior Vice President, Biology at Achaogen.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.